New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
Adjust this page to suit you. Your choices are saved in this browser.
Cookies. Chipokia uses one cookie, and only if you allow it: a random ID so your up and down votes stay yours. No analytics, no advertising, no tracking of any kind. Privacy & Cookie Policy.
